Actuate Therapeutics, Inc. (ACTU)
NASDAQ: ACTU · Real-Time Price · USD
7.90
+0.32 (4.22%)
Mar 28, 2025, 4:00 PM EDT - Market closed

Actuate Therapeutics Stock Forecast

Stock Price Forecast

The 1 analyst with a 12-month price forecast for Actuate Therapeutics stock has a target of 20, which predicts an increase of 153.16% from the current stock price of 7.90.

Analyst Consensus: Strong Buy
Target Low Average Median High
Price $20 $20 $20 $20
Change +153.16% +153.16% +153.16% +153.16%

Analyst Ratings

According to 1 stock analyst, the rating for Actuate Therapeutics is "Strong Buy". This means that the analyst believes this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating Mar '25
Strong Buy 1
Buy 0
Hold 0
Sell 0
Strong Sell 0
Total 1

Latest Forecasts

Analyst Firm Rating Rating Action Price Target Upside Date
HC Wainwright & Co.
HC Wainwright & Co.
Strong Buy
Initiates
$20
Strong Buy Initiates $20 +153.16% Mar 17, 2025
More Analyst Ratings

Financial Forecast

Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-1.22
from -3.26
EPS Next Year
-1.52
from -1.22
Fiscal Year FY 2022 FY 2023 FY 2024 FY 2025 FY 2026
Period Ending Dec 31, 2022 Dec 31, 2023 Dec 31, 2024 Dec 31, 2025 Dec 31, 2026
Revenue
--
Revenue Growth
-----
EPS
-16.65-17.24-3.26-1.22-1.52
EPS Growth
-----
Forward PE
-----
No. Analysts ---33
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue 20252026
High n/a n/a
Avg n/a n/a
Low n/a n/a

Revenue Growth

Revenue Growth 20252026
High - -
Avg - -
Low - -

EPS Forecast

EPS 20252026
High -1.26 -1.56
Avg -1.22 -1.52
Low -1.18 -1.46

EPS Growth

EPS Growth 20252026
High - -
Avg - -
Low - -
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.